Xalkori Ros1+Nsclc Drug Use Investigation
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 21 Aug 2024 Planned End Date changed from 24 Oct 2025 to 24 Aug 2026.
- 21 Aug 2024 Planned primary completion date changed from 24 Oct 2025 to 24 Aug 2026.
- 11 Jan 2024 Planned End Date changed from 6 Feb 2026 to 24 Oct 2025.